Apolipoprotein A-II isoform as a biomarker for prostate cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 12, 2010
Grant Date -
Oct 9, 2008
app pub date -
Jan 6, 2006
filing date -
Jan 6, 2005
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention provides a protein-based biomarker, ApoA-II isoform, that is useful in determining prostate cancer status in a patient. In particular, the biomarker of this invention is useful to classify a biological sample as prostate cancer or non-prostate cancer. The ability of ApoA-II to detect disease in patients with a normal prostate-specific antigen (PSA) makes the biomarker of this invention useful in identifying indolent disease. The biomarker can be detected by SELDI mass spectrometry, HPLC, PAGE and Western blotting.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully